FDA Approved: ROSUVASTATIN — Supplemental Application (ScieGen Pharmaceuticals, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for rosuvastatin submitted by ScieGen Pharmaceuticals, enabling the marketing of a generic rosuvastatin product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerotic Cardiovascular Disease
• Familial Hypercholesterolemia
• Hypercholesterolemia
• Hyperlipidemia

Drugs mentioned

• Rosuvastatin (rosuvastatin)

Snippet

SUPPL AP for ROSUVASTATIN (ROSUVASTATIN)